/ /

  • linkedin
  • Increase Font
  • Sharebar

    Managing viral eye infection: What clinicians should know

    Recent observations show variability in disease presentation, host immunity

     

    Clinical variability, host immunity

    The clinical features and outcomes seen with viral disease vary greatly among patients with the same microbe, and what causes this is the most important unresolved question in the infectious disease arena. Investigators point to various factors, such as the viral strain, latency site, or host immunity. Dr. Margolis favors the latter.

    He discussed the epidemiology of herpes simplex virus (HSV)-1 ARN, a rare disease that occurs in 1 or 2 people per 5 million annually, despite that 80% of individuals have HSV in them. HSV-1 ARN is not an isolated entity. Affected patients also have a high incidence of a second eye disease and central nervous system involvement in addition to chronic iritis and late relapses.

    “These patients are prone to central HSV infection but not peripheral (skin) disease,” he noted.

    In a look-back investigation, Dr. Margolis and his colleagues found that of 7 patients with ARN, all also had encephalitis, which raises the question about a genetic component.

    When considering immune risk factors for HSV, age and atopy are risks for ocular HSV; the C21orf91 genotype is a risk factor for labial HSV, and the TLR2 polymorphisms are risks for HSV encephalitis.

    “Are these same polymorphisms in these genes responsible for patients who develop HSV-1 ARN?” he asked. This is not isolated to HSV-1 ARN but is apparent in other infectious diseases.

    “We now understand that highly specific allelic polymorphisms predispose a limited number of individuals to diseases caused by viruses that otherwise only rarely cause overt disease,” he said. “A virus present in all of us may cause disease only in those unfortunate enough to have a specific genetic make-up.”

    He added that research is showing a number of single gene variants can convey susceptibility or resistance to various pathogens.

     

    Todd P. Margolis, MD, PhD

    E: [email protected]

    Dr. Margolis has no financial interest in the subject matter.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results